Eli Lilly and Co. (NYSE:LLY) on Thursday released promising long-term data regarding its treatment for Crohn’s disease.

This news comes as the company reported that more than 90% of patients maintained steroid-free remission for three years with Omvoh (mirikizumab-mrkz).

The latest data from Eli Lilly’s Phase 3 VIVID-2 study revealed clinical remission of 92.4%, and Corticosteroid-free clinical remission of 91.2%.

Additional data presented from the Phase 3 VIVID-1 (Crohn’s disease) and LUCENT-3 (Ulcerative colitis UC) trials showed Omvoh-treated patients experienced minimal hospitalizations and surgeries across both major types of inflammatory bowel disease (IBD).

In VIVID-1, Omvoh reduced Crohn’s disease-related hospitalizations and/or surgeries by nearly half versus placebo in the first 12 weeks (incidence rate: 16.9 vs. 30.9 per 100 patient-years), and by nearly 70% during weeks 12 to 52 (4.5 vs. 14.0).

In LUCENT-3, one UC-related hospitalization and no UC-related surgeries were reported by patients treated with Omvoh during the three-year long-term extension.

In the context of this data, Omvoh stands out as the only IL-23p19 inhibitor to demonstrate durable efficacy over extended periods, ...